Augmedix Names Tomer Levy as New Senior Vice President of Engineering
With deep experience in developing operational efficiency and innovation, Levy will be working to aid Augmedix in scaling its products, accelerating product development, and aligning with the needs of large healthcare enterprises
SAN FRANCISCO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: AUGX), a healthcare technology company that delivers industry-leading ambient medical documentation and data solutions, today announced that Tomer Levy joined the company in January 2024 in the newly-created Senior Vice President of Engineering role.
Levy brings over 20 years of experience in healthcare information technology. Throughout his career, he has delivered innovative solutions in healthcare IT to large enterprises worldwide.
“We are thrilled to have Tomer join Augmedix as we continue to push the boundaries of AI-powered medical documentation technology to alleviate administrative burden,” said Manny Krakaris, CEO of Augmedix. “Tomer has a distinguished career managing complex, global infrastructures, and having him on the Augmedix team will allow us to optimize engineering performance, streamline product development, and accelerate scalability to health systems across the nation. Tomer's ownership of our production systems will enable our CTO, Saurav Chatterjee, to focus on pushing the frontiers of AI technology embedded in our platform.”
Prior to joining Augmedix, Levy most recently served as Senior Vice President of Research and Development at Change Healthcare. He is passionate about the adoption of cloud technologies that will define a new benchmark for simplicity, cost-effectiveness, cybersecurity, and leveraging data for improved clinical outcomes. Levy worked closely with the Google Cloud Platform team to build a transformative cloud-native solution for medical imaging that set a new standard for scale, reliability, and efficiency.
“It is an exciting time to join Augmedix as the company builds on its leadership in medical documentation and prepares to launch new products and features in the coming months,” said Levy. “I am looking forward to working with this impressive team to further accelerate development and ultimately continue to deliver on Augmedix’s mission of collaborating with hospitals and health systems to improve clinician and patient experiences.”
Levy graduated from the executive MBA program at Tel Aviv University and earned a bachelor’s degree in computer science and economics.
About Augmedix
Augmedix (Nasdaq: AUGX) delivers industry-leading, ambient medical documentation and data solutions to healthcare systems, physician practices, hospitals, and telemedicine practitioners.
Augmedix is on a mission to help clinicians and patients form a human connection by seamlessly integrating our technology at the point of care. Augmedix’s proprietary platform digitizes natural clinician-patient conversations, which are converted into comprehensive medical notes and structured data in real-time. The company’s platform uses automatic speech recognition, and natural language processing, including large language models, to generate accurate and timely medical notes that are transferred into the EHR.
Augmedix’s products relieve clinicians of administrative burden, in turn, reducing burnout, increasing clinician efficiency, and improving patient access. Through Augmedix’s proprietary platform and bi-directional communication channel, Augmedix is ideally suited to serve as the vehicle for change at the point of care.
Augmedix is headquartered in San Francisco, CA, with offices around the world. To learn more, visit .
Contact Information
Investors:
Matt Chesler, CFA
FNK IR
646-809-2183
Media:
Kaila Grafeman
Augmedix
Forward-Looking Statements
This press release contains "forward-looking statements" that involve a number of risks and uncertainties. Such forward-looking statements include, without limitation, the commitment and development of AI-powered medical documentation technology to alleviate administrative burden, the statement regarding Tomer Levi joining Augmedix and the role he will play in allowing us to optimize engineering performance, streamline product development, and accelerate scalability to health systems across the nation, and the launching of new products and features. Actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in our most recent Form 10-K filed with the U.S. Securities and Exchange Commission on April 17, 2023, as well as other documents that may be filed by us from time to time with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
